Biotech Startups

Aether develops additives that blend into engineering-grade nylons to enable faster, high-throughput fused filament (FFF/FDM) 3D printing while maintaining mechanical strength and dimensional accuracy. Its products serve additive manufacturing users in production, field repair, and prototyping settings.

16 investors

Chai Discovery builds a computer-aided design suite using artificial intelligence to design new molecules and drugs. The platform enables pharmaceutical companies to discover and develop medicines more efficiently by learning the principles of biological structure and interaction.

16 investors

One Health operates a clinical trial platform using canine cancer data to accelerate and de-risk human oncology drug development. The company leverages a dataset of 2 billion datapoints from dogs with naturally occurring cancer to serve as a comparative model for pharmaceutical R&D, helping drug developers validate efficacy and identify biomarkers before human trials.

16 investors

Finless Foods develops cell-cultivated seafood alternatives, starting with Pacific bluefin tuna, aimed at consumers seeking sustainable options that reduce pressure on wild fish stocks. The company uses cellular agriculture to produce cultured fish for the consumer food market.

16 investors

GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear. The test is offered by prescription in the United States and through partnerships with healthcare systems, insurance carriers, and diagnostic platforms.

16 investors

Guardant Health develops blood-based testing (liquid biopsy) for cancer detection and monitoring across all stages of the disease. The company serves oncologists, patients, and biopharmaceutical firms with FDA-approved tests for cancer screening, early-stage risk assessment, and treatment selection.

16 investors

Helix Nanotechnologies develops mRNA-based therapeutics for disease treatment and environmental applications, currently advancing a COVID-19 vaccine candidate for immunocompromised patients and testing interventions targeting climate challenges.

16 investors

Insilico Medicine uses artificial intelligence to discover and develop new drugs, operating an AI-driven platform for pharmaceutical research and development. It collaborates with global biopharma companies and academic institutions on drug discovery projects.

16 investors

Living Carbon develops precision-bred tree varieties and reforestation techniques to convert marginal land into carbon-sequestering ecosystems. The company targets climate mitigation through enhanced photosynthesis and biodiversity restoration.

16 investors

Mammoth Bio develops technology to read and write the code of life, operating in the biotechnology sector.

16 investors

Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals. The platform enables faster and more affordable DNA synthesis at scale with customizable high-throughput capabilities.

16 investors

Unnatural Products is a drug discovery platform company that develops synthetic macrocycles to target previously undruggable disease targets. The company focuses on expanding its pipeline of novel therapeutic medicines by leveraging macrocycle chemistry and pharmacokinetics.

16 investors

Alto Neuroscience is a clinical-stage biopharmaceutical company developing biology-driven medicines for neuropsychiatric conditions, using measurements of brain biology to predict clinical response and identify patients likely to benefit from its drug candidates. Its initial focus areas include major depressive disorder, bipolar depression, and schizophrenia.

15 investors

Biobot pioneers wastewater epidemiology, monitoring pathogens and substances in sewage to provide real-time public health surveillance at the community level. The company serves public health agencies, vaccine manufacturers, and hospital systems globally.

15 investors

Clear Labs develops fully automated next-generation sequencing (NGS) platforms that process genomic data into insights for research and surveillance applications across infectious disease, food safety, and oncology. The company serves laboratories, food brands, healthcare systems, and diagnostic organizations.

15 investors

NewLimit develops epigenetic reprogramming medicines to extend healthspan and treat age-related diseases at the intersection of computer science and biotechnology. The company builds therapeutic programs that aim to engineer cell identity and reprogram cell age for human patients.

15 investors

Opentrons develops laboratory robots that automate scientific research tasks for scientists and research institutions. The company aims to democratize access to laboratory automation and increase the availability of robotic systems to accelerate discovery in life sciences.

15 investors

Tropic develops improved varieties of tropical crops using gene editing and gene silencing technologies to enhance yield, disease resistance, and climate resilience. The company serves farmers and global consumers by creating staple crops like bananas and rice that reduce pesticide dependency and environmental impact.

15 investors

Akadeum manufactures GMP-compliant ancillary materials for cell and gene therapy applications, specializing in microbubble-based negative selection products. The company serves research, clinical trial, and therapeutic manufacturing environments requiring regulated cell separation products.

14 investors

Biolinq develops glucose-sensing technology based on micro-array biosensors for metabolic health monitoring, including continuous glucose monitoring. The company works in the medical device and diagnostics space, with a team drawn from continuous glucose monitoring and diabetes device backgrounds.

14 investors

Epoch Biodesign develops enzyme recycling technology powered by AI to break down plastic and textile waste into virgin-grade chemical building blocks. The company serves the fashion, apparel, and automotive industries pursuing textile-to-textile and plastic circularity.

14 investors

Glyphic Biotechnologies develops ProSE™, a high-throughput de novo protein sequencing technology for analyzing proteomes with single-molecule sensitivity. The platform serves research and therapeutic development in proteomics and drug discovery.

14 investors

Molecule operates a blockchain-based platform supporting decentralized science (DeSci), funding research projects and connecting scientists and entrepreneurs. It also features labs such as an autonomous AI agent for peptide drug discovery.

14 investors

Verge Labs builds AI models trained on multimodal human patient data to predict drug targets and patient populations for clinical development, primarily in neuroscience and central nervous system (CNS) disease. The company applies frontier AI techniques to drug discovery for life sciences and pharmaceutical development.

14 investors